899 related articles for article (PubMed ID: 27697601)
1. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.
Nascimento AV; Gattacceca F; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Nanomedicine (Lond); 2016 Apr; 11(7):767-81. PubMed ID: 26980454
[TBL] [Abstract][Full Text] [Related]
3. Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Mol Pharm; 2014 Oct; 11(10):3515-27. PubMed ID: 25256346
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
5. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial-Designed Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles for Encapsulation and Delivery of Lipid-Modified Platinum Derivatives in Wild-Type and Resistant Non-Small-Cell Lung Cancer Cells.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Mol Pharm; 2015 Dec; 12(12):4466-77. PubMed ID: 26523837
[TBL] [Abstract][Full Text] [Related]
7. Near-infrared/pH dual-responsive nanocomplexes for targeted imaging and chemo/gene/photothermal tri-therapies of non-small cell lung cancer.
Li Z; Zhu L; Liu W; Zheng Y; Li X; Ye J; Li B; Chen H; Gao Y
Acta Biomater; 2020 Apr; 107():242-259. PubMed ID: 32151700
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
[TBL] [Abstract][Full Text] [Related]
9. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
10. siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells.
Lu Y; Liu L; Wang Y; Li F; Zhang J; Ye M; Zhao H; Zhang X; Zhang M; Zhao J; Yan B; Yang A; Feng H; Zhang R; Ren X
Biomaterials; 2016 Jan; 76():196-207. PubMed ID: 26524539
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.
Zhang W; Xu W; Lan Y; He X; Liu K; Liang Y
Int J Nanomedicine; 2019; 14():5287-5301. PubMed ID: 31406460
[No Abstract] [Full Text] [Related]
12. Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells.
Chen Y; Sun L; Guo D; Wu Z; Chen W
J Gene Med; 2017 Dec; 19(12):. PubMed ID: 29106062
[TBL] [Abstract][Full Text] [Related]
13. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
14. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
16. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
17. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
18. Demethoxycurcumin-carrying chitosan-antibody core-shell nanoparticles with multitherapeutic efficacy toward malignant A549 lung tumor: from in vitro characterization to in vivo evaluation.
Huang WT; Larsson M; Wang YJ; Chiou SH; Lin HY; Liu DM
Mol Pharm; 2015 Apr; 12(4):1242-9. PubMed ID: 25760774
[TBL] [Abstract][Full Text] [Related]
19. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
